Oryzon Genomics Company Research (0RDB)

Oryzon has presented updated positive data from two Phase Ib iadademstat acute myeloid leukaemia (AML) studies at the European Hematology Association (EHA) 2026 Annual Congress, with the key new information (vs the May update) coming from a larger and more mature ALICE-2 dataset. In ALICE-2 (iadademstat with venetoclax and azacitidine in newly diagnosed AML), 18 evaluable patients achieved a 100% overall response rate (ORR), with an 89% composite complete remission (CRc) rate and a 78% complete response (CR) rate (this builds on the May update, where there were 14 evaluable patients, a 100% ORR, 93% CRc rate and 79% CR rate). Importantly, the EHA data add detail in adverse-risk subgroups, with all patients with TP53 or RAS pathway mutations achieving CR. Median overall survival (OS) was not reached after a median follow-up of eight months, with estimated 12-month OS of 79%. Final ALICE-2 data are expected by year-end, ahead of a potential registrational first-line AML study in 2027. FRIDA data (FLT3-mutated relapsed/refractory (r/r) AML) remained consistent, with a 67% CRc rate, highlighting the promise of the candidate in difficult-to-treat disease settings.